Waking up just one hour earlier could reduce a person’s risk of major depression by 23%, suggests a sweeping new genetic study published May 26 in the journal JAMA… read more.
A new study led by researchers at Washington State University has identified a protein that could be the key to improving treatment outcomes after a heart attack. Published… read more.
Researchers at the Francis Crick Institute have identified a protein that helps tumours evade the immune system and, in certain types of cancers, is linked to a poorer… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase III MAIA (NCT02252172) study showing the addition of Darzalex (daratumumab) to lenalidomide… read more.
The gut and the brain communicate with each other in order to adapt satiety and blood sugar levels during food consumption. The vagus nerve is an important communicator… read more.
Bristol Myers Squibb announced positive topline results from TRANSFORM, a global, randomized, multicenter Phase III study evaluating Breyanzi (lisocabtagene maraleucel) as a second-line treatment in adults with relapsed… read more.
It’s long been known that people living with HIV experience a loss of white matter in their brains. As opposed to “gray matter,” which is composed of the… read more.
The FDA is alerting health care providers to no longer implant end-stage heart failure patients with Medtronic’s Heartware Ventricular Assist Device (HVAD) System due to a growing body… read more.
Immunotherapy with pembrolizumab after surgery significantly improves disease-free survival among patients with the most prevalent form of kidney cancer, clear-cell renal carcinoma. Researchers reported this finding on June… read more.
Genentech, a member of the Roche Group announced the latest data from three pivotal Phase III studies of Venclexta (venetoclax) – CLL14, MURANO and VIALE-A – to be… read more.
Medtronic plc announced it has received FDA approval for Vanta, a high performance recharge-free implantable neurostimulator (INS) with a device life that can be optimized up to 11… read more.
Researchers at UVA Cancer Center have unveiled important new insights into how hormones known as androgens act on our cells — and the discovery could boost efforts to… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
